HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4,6- diphenyl- 3- (4- (pyrimidin- 2- yl)piperazin- 1- yl)pyridazine

inhibits proinflammatory cytokine production; structure in first souce

Also Known As:

MW01-5-188WH

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - 4,6-diphenyl-3-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine: 2
  - Pyridazines: 11
    - 4,6-diphenyl-3-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine: 2

Experts

1.	Watterson, D Martin: 2 articles (12/2007 - 01/2006)
2.	Behanna, Heather A: 1 article (12/2007)
3.	Guo, Xiaoli: 1 article (12/2007)
4.	Harada, Chikako: 1 article (12/2007)
5.	Harada, Takayuki: 1 article (12/2007)
6.	Kohyama, Kuniko: 1 article (12/2007)
7.	Matsumoto, Yoh: 1 article (12/2007)
8.	Nakamura, Kazuaki: 1 article (12/2007)
9.	Craft, Jeffrey M: 1 article (01/2006)
10.	Guo, Ling: 1 article (01/2006)

Related Diseases

1.	Amyloid Plaque 01/11/2006 - "Oral MW01-5-188WH therapy begun 3 weeks after initiation of intracerebroventricular infusion of human Abeta decreased the numbers of activated astrocytes and microglia and the cytokine levels in the hippocampus without modifying amyloid plaque burden or altering peripheral tissue cytokine upregulation in response to an in vivo inflammatory challenge. "
2.	Body Weight (Weight, Body) 12/01/2007 - "Daily oral administration of MW01-5-188WH at 5mg/kg body weight reduced the clinical scores of EAE mice while having no influence on the disease incidence or animal mortality. "

Related Drugs and Biologics

1.	Cytokines

Related Therapies and Procedures

1.	Intraventricular Infusions
2.	Therapeutics
3.	Oral Administration